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Abstract
The neuropeptide substance-P (SP) is expressed from the TAC1 gene in sensory neurones where it acts as a key
modulator of neurogenic inflammation. The promoter of TAC1 (TAC1prom) plays a central role in the regulation of
the TAC1 gene but requires the presence of a second regulatory element; ECR2, to support TAC1 expression in
sensory neurones and to respond appropriately to signalling pathways such as MAPkinases and noxious induction
by capsaicin. We examined whether the effect of capsaicin on ECR2-TAC1prom activity in larger diameter neurones
was cell autonomous or non- cell autonomous. We demonstrate that TRPV1 is not expressed in all the same cells
as SP following capsaicin induction suggesting the presence of a non-cell autonomous mechanism for TAC1 up-
regulation following capsaicin induction. In addition, we demonstrate that induction of SP and ECR1-TAC1prom
activity in these larger diameter neurones can be induced by potassium depolarisation suggesting that, in addition
to capsaicin induction, transgene activity may be modulated by voltage gated calcium channels. Furthermore, we
show that NK1 is expressed in all SP- expressing cells after capsaicin induction and that an agonist of NK1 can
activate both SP and the transgene in larger diameter neurones. These observations suggest the presence of an
autocrine loop that controls the expression of the TAC1 promoter in sensory neurones. In contrast, induction of
the TAC1 promoter by LPS was not dependent on ECR2 and did not occur in large diameter neurones. These
studies demonstrate the diversity of mechanisms modulating the activity of the TAC1 promoter and provide novel
directions for the development of new anti-inflammatory therapies.
Introduction
The neuropeptide substance P (SP), encoded by the
Tachykinin 1 (TAC1) gene, acts as a key regulator of
neurogenic inflammation [1,2]. Consistent with this role
SP is usually expressed in nociceptive C-fibre sensory
neurones within the dorsal root ganglia (DRG) [2]. In
addition, it has been established that the expression of SP
is up-regulated in larger diameter A and B fibre sensory
neurones following noxious stimulation, an expression
pattern also associated with the development of inflam-
matory pain and hyperalgesia [3,4]. Therefore, gaining a
better understanding of the mechanisms involved in con-
trolling the expression of the TAC1 gene in sensory neu-
rones will be critical to understanding the mechanisms
responsible for exacerbating the distressing symptoms of
many forms of chronic inflammatory disease.
TAC1 gene expression, in common with the inflam-
matory pain response, is modulated by a number of
different stimuli such as bacterial infection and noxious
stimulation that often results in depolarisation of sen-
sory neurones. Accepted paradigms for each of these
processes include bacterial wall lipopolysaccharide (LPS)
[5,6] capsaicin [7-10] and potassium-induced cell depo-
larisation that have all been shown to modulate TAC1
promoter (TAC1prom) activity [11,12]. Because of the
critical role that TAC1 plays in neurogenic inflamma-
tion we explored whether there was any commonality in
the mechanisms that influence the activity of TAC1-
prom in different populations of sensory neurones fol-
lowing stimulation by capsaicin, LPS or potassium.
In addition to noxious stimulation capsaicin treatment
has been widely used as a model system in the study of
hyperalgesia [13,14]. Capsaicin activates the transient
receptor potential cation channel, subfamily V, member
1 (TRPV1) a major integrator of noxious stimuli that is
expressed on a subset of SP expressing DRG neurones
[7-10]. Capsaicin has also been shown to induce expres-
sion of TAC1 in vivo [9,10] and gene deletions of the
SP-receptor (NK1) significantly reduces the hyperalgesic
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any medium, provided the original work is properly cited.affects of capsaicin [15]. We have previously shown that
capsaicin could induce the activity of TAC1prom but
only in the presence of the evolutionary conserved region
2 (ECR2) enhancer [16]. This synergy could also be
induced by activation of mitogen activated protein kinase
(MAPkinase) pathways and the effects of capsaicin on
ECR2-TAC1prom interaction could be blocked by antag-
onism of mitogen-activated protein kinase kinase (MEK
kinase) [16]. We also revealed that stimulation of sensory
neurones by capsaicin triggers ECR2- TAC1prom
synergy in larger diameter sensory neurones; an expres-
sion of SP associated with hyperalgesia [16]. However, we
were unable to determine whether the effects of capsaicin
were cell autonomous or cell non- autonomous i.e. were
the mechanisms controlling the up-regulation of TAC1-
prom only found within TRPV1 expressing cells or did
these mechanisms involve communication between cells.
Furthermore, if the effects of capsaicin are non-cell
autonomous it is important to determine the communi-
cation pathways that induce ECR2-TAC1prom activity in
large diameter neurones. In addition, because TRPV1
activation depolarises sensory neurones we also asked
how specific the TRPV1-ECR2-TAC1prom relationship
was and whether other methods of cell depolarisation
such as potassium induced depolarisation, could induce
ECR2-TAC1prom synergy [17,18].
Bacterial LPS has also been shown to upregulate the
expression of TAC1 [5,6] and deletion of the TAC1
gene in mice reduces the effects of bacterial sepsis and
LPS induced organ damage [19]. LPS is a potent activa-
tor of both the inflammatory response and the immune
response through its receptor, Toll Like Receptor 4
(TLR4) [20]. It has been shown previously that activa-
tion of the TLR4 receptor triggers MAPkinase or NFB
dependent pathways [21]. However, it is not known
whether TLR4 is expressed on sensory neurones,
whether the MAPkinase of NFB pathways modulate
the effects of LPS on TAC1 expression, whether the
effects of LPS is cell autonomous or whether the ECR2
enhancer is required for TAC1prom activation by LPS.
Using primary cell culture and transgenic explant cul-
ture we examined the mechanisms through which cap-
saicin, potassium mediated cellular depolarisation and
LPS modulate TAC1prom activity within sensory neu-
rones. Our findings demonstrate surprising diversity in
the mechanisms modulating the activity of the TAC1
gene in sensory neurones. Identifying this diversity, as
well as identifying of the components of the different
mechanisms involved, will have an important baring on
the future development of more targeted inflammatory
pain therapies and will represent an important step in
understanding the processes that regulate gene expres-
sion during the inflammatory response.
Primary cell culture and transfection
Neonatal rat dorsal root ganglia (DRGs) were cultured
as described previously [22]e x c e p tf o rt h ef o l l o w i n g
modifications. Following dissociation, DRG’sn e u r o n s
were re-suspended in Amaxa transfection solution. 100
μl of the cell suspension was added to a microcentrifuge
tube containing 2 μg of plasmid DNA before being
placed in an Amaxa cuvette and transfected using a
nucleofector device set at program G-013. 100 ul of cul-
ture media (consisting of Hank’s F12 meida (Gibco),
putrescine, transferrin, BSA, progesterone, sodium sele-
nite, FGF (20 μg/ml), insulin (100 μg/ml) and antibio-
tics) was added to the transfected cell suspension before
being transferred into a culture dish containing 0.3 ml
of culture media. Cells were left in the incubator and
allowed to adhere to poly-L-lysine/laminin coated glass
cover slips. Immediately after Amaxa transfection with
DNA DRG neurons were cultured for 24 hours in a
solution containing respective agonists or antagonists
(See below). After culture, cells were fixed with 4% par-
aformaldahyde and expression of the LacZ gene (bgal)
was visualised by staining with X-gal stain (5 mM K3Fe
(CN)6; 5 mM K4Fe(CN)6; 2 mM MgCl2; 1 mg/ml X-gal)
for two hours. The number of blue DRG neurons as a
percentage of the total number of neurons was assessed
by cell counting on an inverted DIC microscope. Pro-
portions are adjusted relative to a control plasmid con-
taining the CMV promoter that was transfected at the
same time to normalise transfection efficiencies between
different batches of rat neonates.
Transgenic DRG explant analysis and
immunocytochemistry
Whole DRG explants were dissected from ECR2-TAC1-
prom-LacZ transgenic mouse neonates and placed in
the same culture conditions as described above. These
explants were then treated with agonists or antagonists
for 24 hours (see below), fixed in 4% paraformaldehyde
and incubated with 30% sucrose in optimal cutting tem-
perature (OCT) media overnight. Sections were cut with
ac r y o s t a tt o1 0μm thickness, permeabilised with 0.1%
SDS for 5 mins then incubated in 10% foetal calf serum
in tris-buffered saline with 1% triton (TBST) for
10 mins. Sections were washed 3 times for 5 mins in
TBST and treated sequentially in primary antibodies
overnight (rabbit-anti-bGal, 1:200; rat-anti-Substance P,
1:200 (AbCam) Goat-anti Toll-Like-Receptor 4 (TLR4)
or rat anti-NK1 (1:200, Santa Cruz Biotechnology). Anti-
bodies were visualised by incubation with the appropri-
ate secondary antibody (diluted to 1:250) for 40 mins at
room temp (goat-anti-rat Texas red, donkey-anti-Rabbit
ALEXA 488 or Donkey-anti-goat ALEXA 488, all from
Molecular Probes).
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Lipopolysaccharide, purchased from Sigma-Aldrich, was
dissolved in PBS and used at a concentration of 10 μg/ml
[23]). Capsaicin, purchased from Sigma-Aldrich, was dis-
solved in EtOH and used at a concentration of 10 μM [24].
Forskolin, obtained from Sigma, was dissolved in DMSO
and used at a concentration of 10 μM [25]. [Sar9, Met(O2)
11]-Substance P was obtained from Tocris, dissolved in
H2O and used at a concentration of 100 nM as recom-
mended by Tocris. KCl was obtained from Tocris, dis-
solved in H2O and used at a concentration of 30 mM [26].
Constructs
Details of the production of the constructs used in the
current study have been described previously [16].
Image capture and analysis
Images were captured on Qicam monochrome camera
mounted on a Nicon Eclipse 400 fluorescence micro-
scope and processed using Improvision Velocity soft-
ware v4.1. Figures were assembled on Adobe Photoshop
CS3 software.
Statistical analysis
All experiments were repeated a minimum of three
times on separate dates using separate groups of animals
(n ≥ 3). Two tailed student t-tests were used to test the
significance of data derived from primary cell cultures.
Unpaired t-tests were used on data derived from trans-
genic explants studies to test the significance of the
changes in the proportion of expressing cells within a
specific cell diameter range. Statistical analysis was done
using Microsoft Excel.
Results
Induction of TAC1 by capsaicin does not occur in all
TRPV1 expressing cells
In our previous study we demonstrated perfect co- expres-
sion between the ECR2-TAC1prom-LacZ transgene and
the SP peptide in larger diameter neurones following treat-
ment of transgenic DRG explants with capsaicin [16]. In
order to determine whether capsaicin induction of SP was
cell autonomous (occured within the same cell) or non-
cell autonomous (required cell-cell communication) we
examined SP and TRPV1 co-expression using immunohis-
tochemistry of mouse neonate DRG explants that had
been exposed to 10 μM capsaicin for 24 hours. These
DRG explants were then cryosectioned and fluorescent
immunohistochemistry was carried out using antisera
raised against TRPV1 and SP (Figure 1A). As described
previously [16] immuno-positive cells were counted and
their diameters were measured. The proportions of cells
expressing either SP or TRPV1 are displayed in Figure 1B
and 1C respectively. Consistent with our previous study
[16] we were able to see a significant increase in the pro-
portion of large diameter DRG neurones expressing SP
following treatment with capsaicin (Figure 1A and 1B).
However, we were unable to detect a correspondingly sig-
nificant up-regulation in either the size or numbers of
cells expressing the TRPV1 protein (Figure 1A and 1C). In
addition, we observed a number of larger diameter neu-
rones that expressed the SP peptide following capsaicin
induction but did not express the TRPV-1 protein (Figure
1A, white arrows).
The ECR2-TAC1prom transgene can be activated by cell
depolarization
We have previously used luciferase assays to determine
how TAC1prom responds to various signalling antagonists
Figure 1 Induction of TAC1 by capsaicin does not occur in all
TRPV1 expressing cells. fluorescent immunohistochemical analysis
of 10 μm sections from mouse neonate DRG explants with (iii and
iv) anti-TRPV1 and (v and vi) anti-SP antibody (i, iii, v) before and
(ii, iv, vi) after 24 hours incubation with 10 μM capsaicin. Ai and ii
represent merged images showing cellular co-localisation of TRPV1
and SP (yellow). White arrow heads highlight cells that express SP
but not TRPV1 after capsaicin treatment. B, and C, graphical analysis
of the size distribution (in microns) of neurones within DRG
explants expressing (B) SP and (C) TRPV1 before (White bar) and
after (black bar) capsaicin treatment (n = 3, total number SP/TRPV1
immunostaining cells counted and measured = 284, *; p < 0.05).
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ulatory elements [16]. However, although luciferase assays
are very sensitive in showing changes in the expression of
genes from large population of cells they are limited in
their ability to give information on either the identity of
these cells in mixed populations or on the numbers of
cells expressing the reporter construct. This is an impor-
tant consideration as previous studies have shown that, in
addition to increasing levels of gene expression [7-10] cap-
saicin also increases the expression of the TAC1 gene in
larger diameter neurones [3,4,27-31]. In order to address
this problem we have previously combined luciferase
assays with cell counting assays using the LacZ gene as the
reporter. For example, using luciferase assays in heteroge-
neous primary DRG culture we show that upregulation of
the activity of TAC1prom by capsaicin or the MAPkinase
agonist angiotensin only occurs in the presence of the
remote ECR2 enhancer [16]. These quantitative observa-
tions were supported by parallel experiments carried out
with a LacZ marker which showed that in the presence of
ECR2, TAC1prom responded to angiotensin and capsaicin
by driving the expression of the LacZ marker in signifi-
cantly greater numbers of cells [16].
Because activation of TRPV1 causes cellular depolari-
sation we wanted to test the specificity of the relation-
ship between TRPV1 and ECR2-TAC1prom and to
determine if potassium depolarisation of primary DRG
neurones transformed with the ECR2-TAC1prom-LacZ
construct (See Figure 2A) could increase the numbers of
neurones expressing the reporter construct. We trans-
fected primary DRG neurone cultures with the ECR2-
TAC1prom-LacZ construct and incubated these cultures
in the presence or absence of a 30 mM solution of KCl.
Following staining with X-gal we then counted the
number of cells that expressed the transgene and were
able to detect a significant increase in the numbers of
cells expressing bgal compared to untreated DRG neu-
rones or neurones treated with forskolin which did not
appear to have any significant effect (Figure 2B).
We also recovered intact DRG explants from neonate
mice transgenic for the ECR2-TAC1prom-LacZ con-
struct and cultured these cells in the presence and
absence of 30 mM KCl [26]. We detected a significant
increase in the number of cells with a diameter greater
that 15 microns expressing the transgene mirroring the
effects previously observed using capsaicin and angio-
tensin [16] (Figure 2C).
Capsaicin can induce the expression of the NK1 receptor
in DRG neurones that also express SP
It is a matter of contention that the NK1 receptor, which
is accepted to be the main receptor of the SP neuropep-
tide, is expressed in DRG neurones [32,33]. However, a
number of studies have since provided evidence of the
expression of the receptor on the cell bodies of DRG
neurones [34-38]. For example NK1 expression was
detected in small DRG neurones by in-situ hybridisation
and its activity was detected by electrophysiology in DRG
cells using specific NK1 antagonists [37]. Furthermore,
the expression of NK1 receptors is up-regulated in spon-
taneously hypertensive rats [35] and in DRG neurones
exposed to prostaglandins [34]. In addition, activation of
NK1 receptors in DRG culture potentiates the effects of
TRPV1 and blockade of these NK1 receptors reduced the
ability of TRPV1 activation to cause hyperalgesia and
pain [38]. Other studies have further suggested the pre-
sence of an NK1-TAC1 autocrine loop in a number of
different cells including DRG [38-42]. We explored the
possibility that, in addition to the activity of TAC1prom,
capsaicin treatment might also affect the expression of
the NK1 receptor. We cultured mouse neonate DRG
explants for 24 hours in the presence of 10 μMc a p s a i c i n
Figure 2 The ECR2-TAC1prom transgene can be activated by
cell depolarisation. A, Diagramatic representation (not to scale)
demonstrating the linear relationships of the components of each of
the different constructs used in the current study. Construction of
these reporter vectors has been previously described [16]. pA; SV40
polyadenylation sequence, lacZ; gene encoding b galactosidase
marker protein, hbgprom; human beta globin promoter, TAC1prom;
TAC1 promoter, ECR2; evolutionary conserved region 2, bent black
arrow; indicates the transcriptional start site of the LacZ marker gene.
B; bar graph demonstrating the proportion of primary DRG neurones
that express bgal (as assayed using X-gal) following their transfection
with pECR2-TAC1prom-LacZ and cultured in the presence of forskolin
or KCl (n > 3, *;p < 0.05, n.s., not significant). Proportions are adjusted
relative to a control plasmid containing the CMV promoter that was
transfected at the same time to normalise transfection efficiencies. C,
graphical analysis of the size distribution (diameter in microns) of
neurones within ECR2-TAC1prom-LacZ transgenic DRG explants
showing the proportion of cells expressing the b-gal before and after
treatment with 30 mM KCl demonstrating a shift in the proportion of
larger diameter cells expressing SP and the receptor (n = 3, No cells
counted/measured = 201, *; p < 0.05).
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antisera raised against the NK1 protein and SP (Figure
3A). As before, we observed a significant increase in the
numbers of larger diameter neurones expressing SP fol-
lowing capsaicin treatment (Figure 3A). In addition, we
found a similar increase in the number and diameter of
cells expressing NK1 (Figure 3A and 3B). Most
significantly, and in contrast to the expression of TRPV1,
N K 1e x p r e s s i o nw a sf o u n di na l lo ft h ec e l l st h a t
expressed the transgene following induction by capsaicin
(Figure 3A).
Activation of the NK1 receptor induces expression of the
ECR2-Tac1prom-LacZ transgene
We provide evidence that expression of the NK1 recep-
tor is induced by capsaicin in larger diameter DRG neu-
rones that also express SP. We next addressed the
possibility that activation of the NK1 receptor could
activate the expression of the ECR2-TAC1prom trans-
gene. To achieve this we treated ECR2-TAC1prom-LacZ
transgenic DRG explants in the presence of the NK1
agonist [Sar9, Met(O2)11]-SP. Following 24 hours incu-
bation with this agonist the expression of both SP and
the bgal protein were examined using fluorescence
immunohistochemistry (Figure 4A and 4B). Cell count-
ing and measurement showed a significant up-regulation
of the expression of both SP and the transgene in large
diameter neurones (Figure 4A and 4B) in a manner
reminiscent of treatment by capsaicin [16].
Induction of TAC1prom by LPS is independent of ECR2
A number of studies have shown that, in addition to
capsaicin, SP expression can be induced by the bacterial
cell wall extract LPS. These data support studies that
show that deletions of the TAC1 gene in mice also
reduce the effects of bacterial sepsis and LPS induced
organ damage [6,19]. We explored the hypothesis that
LPS used a similar regulatory pathway as capsaicin to
up-regulate the activity of TAC1prom. Consistent with
the role of LPS in inducing TAC1 gene expression we
were able to co-localise the expression of the TLR4
receptor in a subset of cells of the DRG that also
expressed SP (Figure 5A white arrows). In order to
determine the effects of LPS on TAC1prom we trans-
fected primary DRG neurones with the TAC1prom-
LacZ, ECR2-hbg-LacZ and ECR2-TAC1prom-LacZ
reporter plasmids (See Figure 2A) and treated these cul-
tures with LPS. We demonstrate that LPS induced the
activity of TAC1prom in a significantly greater number
of cells than the untreated control (Figure 5B). However,
these experiments also show that LPS induction of
TAC1prom did not differ significantly in the presence
or absence of ECR2 (Figure 5B and 5C). Furthermore,
culture of ECR2-TAC1prom-LacZ transgenic DRG
explants with LPS did not significantly change the size
spectrum of the cells expressing the transgene (Figure
5D). Indeed no cells with a diameter greater than 15
microns expressed the transgene or SP following treat-
ment with levels of LPS that were clearly shown to
induce TAC1prom in primary neurones.
Figure 3 Capsaicin can induce the expression of the NK1
receptor in DRG neurones that also express SP. A. fluorescent
immunohistochemical analysis of 10 μm sections from mouse
neonate DRG explants with (iii and iv) anti-NK1 and (v and vi) anti-
SP antibody (i, iii, v) before and (ii, iv, vi) after 24 hours incubation
with 10 μM capsaicin. Ai and ii represent merged images showing
cellular co-localisation of NK1 and SP (yellow). B, graphical analysis
of the size distribution (in microns) of neurones within mouse neonate
DRG explants showing the proportion of cells expressing both SP and
NK1 expression before and after capsaicin treatment demonstrating a
shift in the proportion of larger diameter cells expressing SP and the
receptor (n = 3, No cells counted/measured = 242, *; p < 0.05).
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Neurogenic inflammation has been shown to play a cri-
tical role in the progression of diseases such as asthma,
inflammatory bowel disease and arthritis [43]. Thus,
gaining a better understanding of the mechanisms con-
trolling the activity of TAC1prom has been a continuing
priority since the discovery of the involvement of the
TAC1 gene in neurogenic inflammation. We have pre-
viously demonstrated the novel requirement by TAC1-
prom for the presence of the ECR2 enhancer to respond
appropriately to MEKKinase activation and noxious
induction by capsaicin [16]. In the current study, we
have used a combination of transgenic analysis, DRG
explant culture and primary cell line transformation to
further examine the effects of well characterised inflam-
matory mediators such as capsaicin and LPS on TAC1
promoter activity. We first demonstrated that the
expression of TRPV1 did not change significantly in
response to capsaicin and that many of the larger dia-
meter neurones, that expressed substance-P in response
to capsaicin, did not express TRPV1. These observations
suggest that the induction of TAC1 promoter activity in
larger diameter neurones by capsaicin is not cell autono-
mous. Furthermore, we demonstrate that depolarising
D R Gn e u r o n e sw i t hp o t a s s i u mw a sa l s oa b l et oi n d u c e
expression of the transgene in large diameter neurones
providing further evidence tha tt h ep r e v i o u s l yo b s e r v e d
relationship between TRPV1 and the transgene depends
on cell depolarisation. However, we also suggest that the
induction of ECR2-TAC1prom synergism by potassium
induced depolarisation might also activate voltage gated
calcium channels (VGCC) that are also known to play a
role in pain modulation in sensory neurones [44]. These
observations support the hypothesis that TRPV1 is only
one of many pathways that can stimulate synergy
between ECR2 and the TAC1prom.
Because a number of previous studies have reported
the expression of NK1 in these neurones, and also
report on the possibility of an NK1-TAC1 autocrine
loop, we next explored the possibility that the NK1
receptor may be involved in the induction of TAC1-
prom in DRG neurones [34,35,37,38]. In support of
these observations we were able to show a parallel
induction of NK1 and SP in larger diameter DRG neu-
rones following capsaicin treatment. Significantly, we
were also able to observe that treatment of ECR2-
TAC1prom-LacZ transgenic DRG explants with an NK1
agonist triggered the expression of the transgene in
large diameter neurones in a similar way to capsaicin.
These observations are consistent with the proposition
that stimulation of large diameter neurones with SP can
induce the expression of SP within these neurones and
i n d u c ea na u t o c r i n el o o p .T h ep r e s e n c eo fa nT A C 1
gene driven autocrine loop in these large diameter neu-
rones suggests a possible mechanisms for the induction
and maintainance of hyperalgesia which is associated
with the expression of SP in large diameter neurones
[3,4]. However, it must be recognised that [Sar9, Met
(O2)11]-SP can also bind a number of other receptors,
including NK2 and NK3, although with greatly reduced
affinity [45]. Therefore, whilst there is a strong case for
Figure 4 Activation of the NK1 receptor induces expression of
the ECR2-Tac1prom-LacZ transgene. A. Fluorescent
immunohistochemical analysis of 10 μm sections from ECR2-
TAC1prom-LacZ transgenic DRG explants with (iii and iv) anti-SP and
(v and vi) anti-bgal antibody (i, iii, v) before and (ii, iv, vi) after 24
hours incubation with 100 nM NK1 agonist [Sar9, Met(02)11]-SP. Ai
and ii represent merged images showing cellular co-localisation of
NK1 and SP (yellow). B graphical analysis of the size distribution (in
microns) of neurones within ECR2-TAC1prom-LacZ transgenic DRG
explants showing the proportion of cells expressing both SP and
bgal expression before and after [Sar9, Met(01)11]-SP treatment
demonstrating a shift in the proportion of larger diameter cells
expressing SP and the receptor (n = 3, No cells counted/measured =
407, *; p < 0.05).
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prom activity in large diameter neurones following cap-
saicin treatment we are also aware that NK1 may not be
the only receptor responsible and that redundancy with
other receptors, such as NK3, is a possibility. In addi-
tion, although we present evidence for the presence of
an NK1-ECR2-TAC1prom driven autocrine loop in the
perpetuation of SP expression in large diameter neu-
rones there is the possibility that another pathway,
which does not involve NK1 signalling, is involved in
the initial up-regulation of the NK1 gene expression in
large diameter neurones
Following stimulation with KCL or capsaicin it was
observed that the expression of the ECR2-TAC1prom-
LacZ transgene or the NK1 receptor respectively were
observed in significantly lower proportions of small
diameter neurones. However, we have little evidence
that the numbers of small diameter neurones expressing
these markers decrease significantly after treatment.
Therefore, these observations do not constitute a signifi-
cant change in the numbers of cells expressing the
respective marker but instead reflect a reduction in
the overall proportion of small diameter cells expressing
the marker as a result of the increased proportion of
expressing larger diameter neurones.
Based on these observations and those of other studies
described above we present one possible model of the
mechanisms regulating TAC1 promoter activity in sen-
sory neurones in the absence or presence of capsaicin
and potassium (see Figure 6). We propose that, prior to
stimulation by capsaicin, LPS or potassium TAC1prom
is only active in smaller diameter C-fibre neurones
Figure 5 Induction of TAC1prom by LPS is independent of ECR2. A; immunohistochemical analysis of the expression of (i) TLR4 and (ii)S P
and in mouse neonate DRG. iv; merged images and cells co-expressing SP and TRL4 are highlighted in yellow (white arrows). Scale bar = 23
microns. B; bar graph demonstrating the proportion of primary DRG neurones that express bgal (as assayed using X-gal) following their
transfection with each of the constructs shown in figure 2A and cultured in the absence or presence of LPS (n > 3). Proportions are adjusted
relative to a control plasmid containing the CMV promoter that was transfected at the same time to normalise transfection efficiencies. C;
statistical analysis of data from the previous graph demonstrating that average induction rates for TAC1prom-LacZ by LPS is not significantly
affected by the presence of ECR2. D; graphical analysis of the size distribution (in microns) of neurones within ECR2-TAC1prom-LacZ transgenic
DRG explants analysing transgene expression following culture in the absence or presence of LPS (n = 3) demonstrating a lack of a shift in the
proportion of larger diameter cells expressing bgal (n = 3, no. bgal cells counted and measured = 170).
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activity of TAC1prom in larger diameter neurones prior
to cell depolarisation (Step 3). However, following acti-
vation of TRPV1 ion channels with capsaicin or activa-
tion of VGCC’s with potassium driven depolarisation
(step 4) SP containing c-fibre neurones are depolarised
and release SP (step 5 and 6). Following its release, SP
then binds receptors that likely include the NK1 recep-
tor on neighbouring cells (Step 6) triggering an auto-
crine loop (steps 7-10) that results in a parallel
induction of TAC1prom and higher expression of NK1.
These observations, when combined with those from
our previous study [16] suggest the fascinating possibi-
lity that the presence of an autocrine loop in large dia-
meter neurons may contribute to the perpetuation of
hyperalgesic symptoms. Indeed, such an autocrine loop
has been previously suggested in sensory neurons before
[38]. It will be interesting to determine the mechanisms
that allow induction of TAC1prom in larger diameter
n e u r o n e sb yE C R 2 .W h i l s ti ti sp o s s i b l et h a tt h ef u n c -
tion of ECR2, and the MAPkinase activated transcrip-
tion factors interacting with it [16], is to directly
enhance the activity of RNA polymerase II at TAC1-
prom it is also possible that an unidentified MEK/ERki-
nase activated transcription factor allows RNA polII
activity at TAC1prom by removing the repressive effects
of REST/NRSF known to bind at TAC1prom [46,47].
LPS was also shown to increase the numbers of pri-
mary neurones in which TAC1prom was active. How-
ever, in contrast to angiotensin and capsaicin [16]
induction of TAC1prom by LPS did not depend on the
presence of ECR2. In addition, we were unable to detect
any evidence for the upregulation of the TAC1prom
transgene in neurones greater that 15 microns in dia-
meter in DRG explants exposed to LPS. Our data sug-
gests that activation of TAC1prom by LPS is via an
unidentified cell autonomous mechanisms that does not
require the presence of ECR2 (step 11). We have pre-
viously shown that angiotensin II is unable to activate
TAC1prom in the absence of ECR2 [16] Although LPS
binding to TLR4 has been shown to activate MAPkinase
pathways the lack of requirement by LPS for ECR2 in
the induction of TAC1prom, in combination with the
inability of MAPkinase to induce TAC1prom in the
absence of ECR2, suggests that LPS does not control
TAC1prom through MAPkinases. Thus, by deduction,
L P Si sm o r el i k e l yt om o d u l a t eT A C 1 p r o ma c t i v i t y
through NFb than MAPkinase pathways [21]. In keep-
ing with this hypothesis there have been previous
reports of highly conserved NFb binding in TAC1
Figure 6 Diagrammatical representation of the hypothetical genomic and cellular events that affect the activation of TAC1prom in
sensory neurones treated with KCl, capsaicin or LPS. This model is based on the conclusions of the current study and the literature. See the
discussion section in the main text for a detailed description.
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Page 8 of 10exon 1 [48] and we have used bioinformatics to detect
t h ep r e s e n c eo fN F b binding sites close to the human
TAC1 transcriptional start site (data not shown).
Despite evidence showing that LPS and capsaicin can
activate TAC1 expression and inflammation the current
study suggests a distinction between the signal transduc-
tion pathways that control either capsaicin or LPS acti-
vation of TAC1prom. In hindsight, the basis for these
differences make sense as, despite both being able to
activate the promoter, they are both known to operate
through different signalling pathways [13,21]. Further
analyses of the influence of NFb on activation of
TAC1prom in sensory neurones exposed to LPS will be
very exciting.
Conclusions
The current study sheds light on the fascinating diver-
sity of regulatory mechanisms that control the activity
of TAC1prom during challenges by inflammatory med-
iators such as LPS and capsaicin and provides further
evidence for the existence of an auto-regulatory loop
that controls the expression of the TAC1 gene
[34,35,37,38]. Gaining a better understanding of the
diverse mechanisms that control the expression of
TAC1prom during the inflammatory response will take
us a step nearer to the development of more specific
and novel therapies for the treatment of conditions such
as hyperalgesia and inflammatory pain.
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